Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Tirzepatide

Dual GIP and GLP-1 Receptor Agonist

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Available as FDA-approved Mounjaro® for Type 2 diabetes and Zepbound® for weight management and obstructive sleep apnea. It provides superior weight loss and glycemic control compared to single-pathway medications through its unique dual mechanism of action.

Tirzepatide Dosing Guide

What It's Used For

Tirzepatide is a dual GIP/GLP-1 receptor agonist that revolutionizes treatment for both type 2 diabetes and weight management. It's the first medication to target both incretin pathways, providing superior results compared to single-receptor drugs.

Weight Loss (Zepbound®)

  • FDA-approved for chronic weight management
  • Average weight loss of 15-22% of body weight
  • Also approved for obstructive sleep apnea (OSA)

Type 2 Diabetes (Mounjaro®)

  • Improves glycemic control when combined with diet and exercise
  • Reduces HbA1c by 2.0-2.3%
  • Provides significant weight loss as secondary benefit

Metabolic Health

  • Improves insulin sensitivity
  • Reduces cardiovascular risk factors
  • Lowers blood pressure and improves lipid profiles

Appetite Regulation

  • Slows gastric emptying
  • Increases satiety signals
  • Reduces food cravings

How Much to Take

Weeks 1-4
2.5 mg once weekly
Initiation (minimize side effects)
Weeks 5-8
5 mg once weekly*
First maintenance dose option
Weeks 9-12
7.5 mg once weekly
Dose escalation if tolerated
Weeks 13-16
10 mg once weekly*
Second maintenance dose option
Weeks 17-20
12.5 mg once weekly
Further escalation if needed
Week 21+
15 mg once weekly*
Maximum maintenance dose

*Indicates recommended maintenance doses

Frequency

Once weekly, same day each week

Timing

Any time of day, with or without food

Adjustment

Increase by 2.5 mg every 4 weeks

How Long to Use It

  • For Weight Loss: Long-term use recommended to maintain results
  • Initial Results: Noticeable weight loss within 8-12 weeks
  • Peak Effects: Maximum weight loss typically achieved by 72 weeks
  • Maintenance: Continue indefinitely to maintain weight loss
  • For Diabetes: Long-term use as part of diabetes management plan

Important

Weight regain is common after discontinuation. Most patients regain weight within 12 months of stopping treatment.

Need-to-Know Information

How It Works

  • Activates both GIP and GLP-1 receptors (dual agonist)
  • Stimulates insulin release when blood sugar is elevated
  • Suppresses glucagon secretion
  • Slows gastric emptying to increase satiety
  • Acts on brain centers controlling appetite

Key Benefits

Skin Quality: 36% reduction in fine lines and 27% improvement in skin clarity

Wound Healing: 40-60% faster healing rate compared to controls

Collagen Production: 24% increase in skin thickness and elasticity

Hair Growth: 22% increase in density and 28% improvement in thickness

Who Should Avoid It

  • Personal or family history of medullary thyroid cancer
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • History of pancreatitis
  • Type 1 diabetes
  • Pregnant or breastfeeding women
  • Severe gastroparesis

Common Side Effects

  • Mild skin irritation (rare, <3% of users)
  • Temporary copper taste with systemic use
  • Minor redness at injection site
  • Temporary skin sensitivity to sunlight
  • Mild burning sensation initially

How to Store and Inject

Storage Before First Use

  • Refrigerate at 36-46°F (2-8°C)
  • Do not freeze
  • Protect from light

Storage After First Use

  • Room temperature for up to 21 days
  • Or continue refrigeration
  • Discard after 21 days if kept at room temperature

Injection Sites

  • Abdomen (preferred)
  • Thigh
  • Upper arm

Injection Method

  • Subcutaneous injection only
  • Rotate sites weekly
  • Never inject same spot consecutively

Injection Tips

  • Remove from fridge 30 min before
  • Clean site with alcohol swab
  • Hold button for 10 seconds

Example Weekly Schedule

  1. Sunday Morning: Take weekly tirzepatide injection
  2. Throughout Week: Maintain regular diet and exercise routine
  3. Next Sunday: Repeat injection at same time

If You Miss a Dose:

  • Within 4 days (96 hours): Take as soon as remembered
  • More than 4 days: Skip missed dose, resume regular schedule
  • Never: Take two doses within 3 days of each other

Extra Tips for Best Results

Managing Side Effects

  • Eat smaller, more frequent meals
  • Avoid fatty, greasy, or spicy foods
  • Stay hydrated with small sips throughout the day
  • Consider anti-nausea medication if needed

Maximize Weight Loss

  • Follow reduced-calorie diet (500-750 deficit)
  • Aim for 150 minutes moderate exercise weekly
  • Include strength training 2-3 times per week
  • Track food intake and body measurements

Monitor Your Progress

  • Weekly weight checks (same time, same conditions)
  • Monthly body measurements
  • Regular blood work (HbA1c, lipids, kidney function)
  • Track side effects and tolerance

Lifestyle Optimization

  • Prioritize protein intake (0.8-1g per pound)
  • Focus on whole, unprocessed foods
  • Manage stress through meditation or yoga
  • Ensure 7-9 hours quality sleep

Expected Results Timeline:

  • Week 4-8: Appetite suppression and initial weight loss (2-4%)
  • Week 12: Significant weight loss visible (5-8%)
  • Week 24: Substantial results (10-15%)
  • Week 52-72: Maximum weight loss achieved (15-22%)

Serious Warning - Seek Immediate Medical Attention If:

  • Severe abdominal pain (possible pancreatitis)
  • Vision changes (diabetic retinopathy)
  • Signs of thyroid tumor (neck lump, hoarseness, difficulty swallowing)
  • Severe allergic reaction (swelling, difficulty breathing)
  • Persistent vomiting or inability to keep fluids down
  • Thoughts of self-harm or unusual mood changes

Medical Disclaimer

Tirzepatide is FDA-approved as Mounjaro® for Type 2 diabetes and Zepbound® for chronic weight management. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.